Well, I mean, I think the main limitation is what we’re seeing across all cancers is what do we do with the results, right? So if I identify somebody that’s ctDNA positive, does it help to start treatment early, maybe before I can see anything on a scan? I think that’s an unanswered question in endometrial cancer especially. So I think that’s one limitation...
Well, I mean, I think the main limitation is what we’re seeing across all cancers is what do we do with the results, right? So if I identify somebody that’s ctDNA positive, does it help to start treatment early, maybe before I can see anything on a scan? I think that’s an unanswered question in endometrial cancer especially. So I think that’s one limitation. And then I think, you know, it’s unfortunately, you know, endometrial cancer is the most common gynecologic malignancy, but it’s often a later area of study. So we just don’t have as much data in endometrial cancer as we do in some of the other solid tumors. And there are ctDNA assays that are already clinically available. And I see people in my practice that have gotten those tested, you know, on the outside, but I’m not always sure what to do with it yet. So I think more and more studies like this one that come out with information saying, okay, it can affect prognosis and potentially it can improve treatment, then that gives us something we can do with it. Okay, you have positive ctDNA. Let’s add another drug to your regimen to try to help clear that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
